TTRX · Turn Therapeutics Inc.

Turn Therapeutics Inc. (TTRX) reported Q1 FY2026 results reflecting the realities of a clinical-stage biotech advancing its GX-03 program. Operating income stood at -$1.2M under GAAP, driven primarily by the increase in research and development expenses from the ongoing Phase-2 equivalent study of GX-03 in moderate-severe Alzheimer's disease (AD). This investment underscores the company's commitment to progressing its lead asset through critical clinical milestones, where ramped-up trial activities directly elevate costs as patient enrollment, site management, and data collection intensify.

Net income was -$971K, translating to diluted EPS of -$0.03. This outcome incorporates non-cash derivative liability fair value changes, which provided some offset to the underlying operating pressures. Investors should note that such adjustments arise from warrants and convertibles tied to recent financings, highlighting how accounting for these instruments impacts reported bottom-line results without reflecting cash economics. The narrowing of net loss relative to operating loss illustrates this dynamic, but the core story remains one of R&D intensity.

Management's outlook emphasizes that expenses and operating losses will increase substantially for the foreseeable future, tied directly to higher R&D for later-stage trials. This forward guidance aligns with the current GX-03 trajectory and signals prudent planning for scale-up. Liquidity remains a focus: existing cash, cash equivalents, and short-term investments are believed sufficient to cover operating expenses and capital needs into Q1 2027. This runway provides breathing room to execute on clinical objectives without immediate funding pressure.